Alkermes plc ALKS
45.90 USD +1.36 (+3.05%)
At closeNov 6, 2026, 5:23 PM EST
45.90 0.00 0.00%
After hours · Nov 6, 5:23 PM ET
44.07 Day range 45.94
27.00 52-week range 55.67
- YTD
- +64.05%
- 1 year
- +44.89%
News
benzinga.com RBC Capital Maintains Outperform on Alkermes, Raises Price Target to $57 RBC Capital analyst Leonid Timashev maintains Alkermes (NASDAQ:ALKS) with a Outperform and raises the price target from $56 to $57.- benzinga.com Wells Fargo Maintains Overweight on Alkermes, Raises Price Target to $68 Wells Fargo analyst Benjamin Burnett maintains Alkermes (NASDAQ:ALKS) with a Overweight and raises the price target from $65 to $68.
benzinga.com HC Wainwright & Co. Maintains Neutral on Alkermes, Raises Price Target to $50 HC Wainwright & Co. analyst Douglas Tsao maintains Alkermes (NASDAQ:ALKS) with a Neutral and raises the price target from $43 to $50.
seekingalpha.com Alkermes plc (ALKS) Q3 2026 Earnings Call Transcript Alkermes plc ( ALKS ) Q3 2026 Earnings Call November 3, 2026 8:00 AM EST Company Participants Sandra Coombs - Senior Vice President of Corporate Affairs & Investor Relations Blair Jackson -…
marketbeat.com What Alkermes (ALKS) Said on Its Q3 Earnings Call Alkermes NASDAQ: ALKS reported third-quarter 2026 results marked by 31% year-over-year growth in proprietary product sales, while management highlighted continued investment in its orexin development…
zacks.com Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Alkermes (ALKS) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall…
benzinga.com Alkermes Q3 2026 Earnings Call Transcript Alkermes (NASDAQ:ALKS) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
zacks.com Alkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimates Alkermes (ALKS) came out with quarterly earnings of $0.09 per share, beating the Zacks Consensus Estimate of a loss of $0.08 per share. This compares to earnings of $0.49 per share a year ago.
benzinga.com Alkermes Q3 EPS $0.09 Beats $(0.06) Estimate, Sales $480.100M Beat $463.606M Estimate Alkermes (NASDAQ:ALKS) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $(0.06) by 250 percent. This is a 81.63 percent decrease over earnings of $0.49 per…
benzinga.com Alkermes Affirms FY2026 Sales Guidance of $1.730B-$1.840B vs $1.822B Est Alkermes (NASDAQ:ALKS) affirms FY2026 sales outlook from $1.730 billion-$1.840 billion to $1.730 billion-$1.840 billion vs $1.822 billion estimate.
businesswire.com Alkermes plc Reports Third Quarter 2026 Financial Results DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended September 30, 2026. To view the detailed third quarter 2026 earnings press release and…
defenseworld.net Alkermes (NASDAQ:ALKS) vs. Vericel (NASDAQ:VCEL) Head to Head Contrast Vericel (NASDAQ: VCEL - Get Free Report) and Alkermes (NASDAQ: ALKS - Get Free Report) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Inovio Pharmaceuticals (NASDAQ:INO) shares increased by 232.0% to $2.0 during Monday's pre-market session. The company's market cap stands at $62.2 million. AngioDynamics (NASDAQ:ANGO) shares…
businesswire.com Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD) DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the initiation of a phase 2 study evaluating the safety and efficacy of ALKS 7290 as an adjunctive therapy to antidepressants in…
benzinga.com Alkermes Plans To Present Two Oral Presentations And Six Posters From Portfolio Of Sleep Medicine Research At ESRS 28th Congress, Sleep Europe 2026 — Data From Vibrance-1 Phase 2 Study Lancet Neurology Publication Evaluating Alixorexton in Narcolepsy Type 1 and Additional Data From Long-Term Extension Study in Narcolepsy Type 1 and Type 2 to be…
benzinga.com Goldman Sachs Reinstates Neutral on Alkermes, Announces $50 Price Target Goldman Sachs analyst Andrea Newkirk reinstates Alkermes (NASDAQ:ALKS) with a Neutral and announces $50 price target.- benzinga.com RBC Capital Reiterates Outperform on Alkermes, Maintains $56 Price Target RBC Capital analyst Leonid Timashev reiterates Alkermes (NASDAQ:ALKS) with a Outperform and maintains $56 price target.
benzinga.com Meta To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Tuesday Analysts upgraded Fifth Third to Buy and adjusted price targets for Exelon, Alaska Air, Fair Isaac, Meta, Alkermes, Twilio and Warner Bros. Discovery.- benzinga.com Baird Maintains Outperform on Alkermes, Raises Price Target to $61 Baird analyst Joel Beatty maintains Alkermes (NASDAQ:ALKS) with a Outperform and raises the price target from $58 to $61.
benzinga.com Alkermes Says Experimental Drug Could Open New Path in ADHD Treatment Alkermes reports positive Phase 1b data for ALKS 7290, showing clinical proof-of-concept for ADHD treatment. Learn key findings.- benzinga.com Alkermes Shares Topline Results From Phase 1 Proof-of-concept Study Evaluating ALKS 7290 For Attention-deficit Hyperactivity Disorder, Showing Meaningful Improvements In Patients Alkermes plc (NASDAQ:ALKS) today announced positive topline results from a phase 1 proof-of-concept study evaluating ALKS 7290, the company’s novel, investigational orexin 2 receptor (OX2R) agonist…
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Alkermes Terminates VIVITROL Authorized Generic Supply Agreement With Amneal Without Penalties On July 6, 2026, Alkermes plc (the "Company") and Amneal Pharmaceuticals LLC ("Amneal") terminated the previously disclosed Authorized Generic Product Supply Agreement entered into on September 9,…
benzinga.com This Liquidia Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday Top Wall Street analysts changed outlook on top stocks. See all changes including upgrades, downgrades, and initiations on analyst ratings page.
benzinga.com Micron To Rally Around 44%? Here Are 10 Top Analyst Forecasts For Thursday Top analysts changed outlook on top names: Intuit downgraded, Alkermes price target raised, Carmax target increased, Sezzle target up, Biogen target raised, Progressive target cut.
benzinga.com Venu Holding Pursues $80M Sale-Leaseback Transaction On Parking Garage Asset At Sunset Amphitheater In McKinney, Texas Company seeks to advance national expansion through innovative financing model; Founder personally invested in Company's first sale-leaseback transaction as part of an approximately $250 million…
benzinga.com Earnings Scheduled For May 5, 2026 
benzinga.com Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen for $41/share. Other gainers incl. Centessa, Annexon, Agios, Fulcrum, Scholar Rock, Alkermes, Wave…- benzinga.com Earnings Scheduled For February 25, 2026
benzinga.com Southern To Rally More Than 9%? Here Are 10 Top Analyst Forecasts For Friday 
benzinga.com Jim Cramer Says Sell Super Micro — Calls A European Chipmaker 'Cheap And Good' Jim Cramer recommended selling Super Micro Computer Inc. and doesn't recommend Alkermes plc. Huntington Bancshares is 'terrific.' Smith & Nephew plc should be sold. Cramer also recommends buying…
benzinga.com 10 Health Care Stocks With Whale Alerts In Today's Session - benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com This Alkermes Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday 
benzinga.com Earnings Scheduled For October 28, 2025 
benzinga.com Deal Dispatch: From Four Roses Bourbon To Quantum Stakes, Here Are This Week's Sector Shake Ups Four Roses, Six Flags, and Trump's potential Quantum investments: This week's deal activity involves big bets across various sectors.
benzinga.com This Ciena Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
benzinga.com Macy's Increases FY2025 Outlook, Joins REV Group, HealthEquity, Alphabet and Wellness And Other Big Stocks Moving Higher On Wednesday 
benzinga.com This Unisys Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday 
benzinga.com Bruker, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - benzinga.com Earnings Scheduled For July 29, 2025
benzinga.com Nvidia To Rally More Than 38%? Here Are 10 Top Analyst Forecasts For Tuesday 
benzinga.com This Arista Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday 
benzinga.com Earnings Scheduled For May 1, 2025 
benzinga.com Stocks Trim Losses After Hot Inflation, Bonds Remain Pressured, Tesla Rebounds: What's Driving Markets Wednesday? A hotter-than-expected inflation report initially rattled markets on Wednesday morning, but investors found confidence to buy the dip, helping major indexes recover most losses by midday trading in…- benzinga.com Earnings Scheduled For February 12, 2025
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
benzinga.com AT&T, Group 1 Automotive, Mattel, Seagate And Other Big Stocks Moving Higher On Wednesday - benzinga.com Earnings Scheduled For February 15, 2024 Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million.